Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

SLC35B2 Expression is Associated with a Poor Prognosis of Invasive Ductal Breast Carcinoma

  • Chim-ong, Anongruk (Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University) ;
  • Thawornkuno, Charin (Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University) ;
  • Chavalitshewinkoon-Petmitr, Porntip (Department of Protozoology, Faculty of Tropical Medicine, Mahidol University) ;
  • Punyarit, Phaibul (Army Institute of Pathology, Phramongkutklao Medical Center) ;
  • Petmitr, Songsak (Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University)
  • Published : 2014.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Breast cancer is the most common malignancy in women worldwide, including Thailand, and is a major cause of mortality and morbidity, despite advances in diagnosis and treatment. Novel gene expression in breast cancer is a focus in searches for prognostic biomarkers and new therapeutic targets. Materials and Methods: The mRNA expression of novel B4GALT4, SLC35B2, and WDHD1 genes in breast cancer were examined in invasive ductal breast carcinoma (IDC) patients using quantitative real-time reverse transcription polymerase chain reaction (QRT-PCR). Results: Among these genes, increased expression of SLC35B2 mRNA was significantly associated with TNM stage III + IV of IDC (p<0.001). Hence, up-regulation of SLC35B2 may serve as a prognostic biomarker for poor prognosis, and is also a potential therapeutic target in breast cancer.

Keywords

References

  1. Arnutti P, Kotepui M, Asanprakit W, et al (2013). Determination of whole transcription profiles and specific pathways in invasive ductal breast carcinoma. Int J Clin Exp Pathol, 6, 1112-20.
  2. Al-Kuraya K, Schraml P, Torhorst J, et al (2004). Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res, 64, 8534-40. https://doi.org/10.1158/0008-5472.CAN-04-1945
  3. Berry DA, Cronin KA, Plevritis SK, et al (2005). Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med, 353, 1784-92. https://doi.org/10.1056/NEJMoa050518
  4. Blackwell KL, Burstein HJ, Storniolo AM, et al (2010). Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumabrefractory metastatic breast cancer. J Clin Oncol, 28, 1124-30. https://doi.org/10.1200/JCO.2008.21.4437
  5. Chuthapisith S, Permsapaya W, Warnnissorn M, et al (2012). Breast cancer subtypes identified by the ER, PR and HER-2 status in Thai women. Asian Pac J Cancer Prev, 13, 459-62. https://doi.org/10.7314/APJCP.2012.13.2.459
  6. De Giorgi U, Rosti G, Frassineti L, et al (2007). High-dose chemotherapy for triple negative breast cancer. Ann Oncol, 18, 202-3.
  7. de Snoo F, Bender R, Glas A, Rutgers E (2009). Gene expression profiling: decoding breast cancer. Surg Oncol, 18, 366-78. https://doi.org/10.1016/j.suronc.2009.07.005
  8. Eeckhoute J, Carroll JS, Geistlinger TR, Torres-Arzayus MI, Brown M (2006). A cell-type specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev, 20, 2513-26. https://doi.org/10.1101/gad.1446006
  9. Edge SB, Compton CC (2010). The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 17, 1471-4. https://doi.org/10.1245/s10434-010-0985-4
  10. Ekpanyaskul C, Khuhaprema T, Wiangnon S, Sangrajrang S (2010). Case-control study of occupational categories and breast cancer risk in Thailand. Asian Pac J Cancer Prev, 11, 793-7.
  11. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  12. Fitzgibbons PL, Page DL, Weaver D, et al (2000). Prognostic factors in breast cancer. college of american pathologists consensus statement 1999. Arch Pathol Lab Med, 124, 966-78.
  13. Frkovic-Grazio S, Bracko M (2002). Long term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma. J Clin Pathol, 55, 88-92. https://doi.org/10.1136/jcp.55.2.88
  14. Ginzinger DG (2002). Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp Hematol, 30, 503-12. https://doi.org/10.1016/S0301-472X(02)00806-8
  15. Goda E, Kamiyama S, Uno T, et al (2006). Identification and characterization of a novel Drosophila 3'-phosphoadenosine 5'-phosphosulfate transporter. J Biol Chem, 281, 28508-17. https://doi.org/10.1074/jbc.M605045200
  16. Huopaniemi L, Kolmer M, Niittymaki J, Pelto-Huikko M, Renkonen R (2004). Inflammation-induced transcriptional regulation of Golgi transporters required for the synthesis of sulfo sLex glycan epitopes. Glycobiology, 14, 1285-94. https://doi.org/10.1093/glycob/cwh131
  17. Ismail-Khan R, Bui MM (2010). A review of triple-negative breast cancer. Cancer Control, 17, 173-6.
  18. Jana D, Mandal S, Mukhopadhyay M, et al (2012). Prognostic significance of HER-2/neu and survival of breast cancer patients attending a specialized breast clinic in Kolkata, Eastern India. Asian Pac J Cancer Prev, 13, 3851-5. https://doi.org/10.7314/APJCP.2012.13.8.3851
  19. Kamiyama S, Suda T, Ueda R, et al (2003). Molecular cloning and identification of 3'-phosphoadenosine 5'-phosphosulfate transporter. J Biol Chem, 278, 25958-63. https://doi.org/10.1074/jbc.M302439200
  20. Kamiyama S, Sasaki N, Goda E, et al (2006). Molecular cloning and characterization of a novel 3'-phosphoadenosine 5'-phosphosulfate transporter, PAPST2. J Biol Chem, 281, 10945-53. https://doi.org/10.1074/jbc.M508991200
  21. Kamiyama S, Ichimiya T, Ikehara Y, et al (2011). Expression and the role of 3'- phosphoadenosine 5'-phosphosulfate transporters in human colorectal carcinoma. Glycobiology, 21, 235-46. https://doi.org/10.1093/glycob/cwq154
  22. Kenemans P, Verstraeten RA, Verheijen RH (2008). Oncogenic pathways in hereditary and sporadic breast cancer. Maturitas, 61, 141-50. https://doi.org/10.1016/j.maturitas.2008.11.010
  23. Khuhaprema T, Srivatanakul P, Sriplung H, et al (2006). Bangkok cancer registry. In 'Cancer in Thailand Vol. IV, 1998-2000' Bangkok Medical Publisher, Bangkok pp 7-21.
  24. Khuhaprema T, Srivatanakul P, Sriplung H, et al (2010). Bangkok cancer registry. In 'Cancer in Thailand Vol. V, 2001-2003' Bangkok Medical Publisher, Bangkok pp 113-8.
  25. Kotepui M, Chupeerach C (2013). Age distribution of breast cancer from a Thailand population-based cancer registry. Asian Pac J Cancer Prev, 14, 3815-17. https://doi.org/10.7314/APJCP.2013.14.6.3815
  26. Kotepui M, Thawornkuno C, Chavalitshewinkoon-Petmitr P, Punyarit P, Petmitr S (2012). Quantitative real-time RTPCR of ITGA7, SVEP1, TNSI1, LPHN3, SEMA3G, KLB and MMP13 mRNA expression in breast cancer. Asian Pac J Cancer Prev, 13, 5879-82. https://doi.org/10.7314/APJCP.2012.13.11.5879
  27. Kuderer NM, Lyman GH (2009). Gene expression profile assays as predictors of distant recurrence-free survival in early-stage breast cancer. Cancer Invest, 27, 885-90. https://doi.org/10.3109/07357900903275142
  28. Li CY, Zhang S, Zhang XB, et al (2013). Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study. Asian Pac J Cancer Prev, 14, 3779-84. https://doi.org/10.7314/APJCP.2013.14.6.3779
  29. Li H, Deyrup A, Mensch JR Jr, et al (1995). The isolation and characterization of cDNA encoding the mouse bifunctional ATP sulfurylase-adenosine 5'-phosphosulfate kinase. J Biol Chem, 270, 29453-9. https://doi.org/10.1074/jbc.270.49.29453
  30. Liu AN, Sun P, Liu JN, et al (2012). Clinicopathologic characteristics and prognostic factors in patients with operable HER-2 overexpressing breast cancer. Asian Pac J Cancer Prev, 13, 1197-201. https://doi.org/10.7314/APJCP.2012.13.4.1197
  31. Luders F, Segawa H, Stein D, et al (2003). Slalom encodes an adenosine 3'-phosphate 5'-phosphosulfate transporter essential for development in drosophila. EMBO J, 22, 3635-44. https://doi.org/10.1093/emboj/cdg345
  32. Moore MA, Attasara P, Khuhaprema T, et al (2008). Cancer epidemiology in mainland south-east asia-past, present and future. Asian Pac J Cancer Prev, 10, 67-80.
  33. Madjd Z, Akbari ME, Zarnani AH, et al (2014). Expression of EMSY, a novel BRCA2-link protein, is associated with lymph node metastasis and increased tumor size in breast carcinomas. Asian Pac J Cancer Prev, 15, 1783-9. https://doi.org/10.7314/APJCP.2014.15.4.1783
  34. Nair R, Roden DL, Teo WS, et al (2013). c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer. Oncogene, (Epub ahead of print).
  35. Nakayama F, Umeda S, Ichimiya T, et al (2013). Sulfation of keratan sulfate proteoglycan reduces radiation-induced apoptosis in human Burkitt's lymphoma cell lines. FEBS Lett, 587, 231-7. https://doi.org/10.1016/j.febslet.2012.12.002
  36. Olivotto IA, Chua B, Allan SJ, et al (2003). Long-term survival of patients with supraclavicular metastases at diagnosis of breast cancer. J Clin Oncol, 21, 851-4. https://doi.org/10.1200/JCO.2003.11.105
  37. Pakkiri P, Lakhani SR, Smart CE (2009). Current and future approach to the pathologist's assessment for targeted therapy in breast cancer. Pathology, 41, 89-99. https://doi.org/10.1080/00313020802563551
  38. Reed W, Hannisdal E, Boehler PJ, et al (2000). The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer, 88, 804-13. https://doi.org/10.1002/(SICI)1097-0142(20000215)88:4<804::AID-CNCR11>3.0.CO;2-Y
  39. Sriplung H, Wiangnon S, Sontipong S, Sumatsawan Y, Martin M (2006). Cancer incidence trends in Thailand, 1989-2000. Asian Pac J Cancer Prev, 7, 118-25.
  40. Singletary SE, Allred C, Ashley P, et al (2002). Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol, 20, 3628-36. https://doi.org/10.1200/JCO.2002.02.026
  41. Taneja P, Maglic D, Kai F, et al (2010). Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance. Clin Med Insights Oncol, 4, 15-34.
  42. Woodward WA, Strom EA, Tucker SL, et al (2003). Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol, 21, 3244-8. https://doi.org/10.1200/JCO.2003.03.052
  43. Yu D, Hung MC (2000). Over-expression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene, 19, 6115-21. https://doi.org/10.1038/sj.onc.1203972
  44. Zhang H, Jin F (2010). HER-2 expression correlates with survivin in primary invasive ductal breast cancers. Asian Pac J Cancer Prev, 11, 1201-4.